Nuvectis Pharma FY2028 EPS Forecast Raised by Roth Capital

Key Points

• Roth Capital has raised its FY2028 earnings per share forecast for Nuvectis Pharma to $2.46, up from a previous estimate of $2.43.
• The company reported a quarterly loss of ($0.30) per share, which missed analysts' expectations of ($0.25) per share.
• Insider Marlio Charles Mosseri increased their stake in Nuvectis Pharma by purchasing 5,603 shares at an average price of $7.99 per share.

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Research analysts at Roth Capital raised their FY2028 earnings per share (EPS) estimates for shares of Nuvectis Pharma in a research report issued on Tuesday, August 12th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of $2.46 per share for the year, up from their previous forecast of $2.43. The consensus estimate for Nuvectis Pharma's current full-year earnings is ($1.01) per share.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.05).

Several other equities research analysts have also commented on NVCT. Wall Street Zen lowered Nuvectis Pharma from a "hold" rating to a "sell" rating in a research report on Sunday, June 29th. HC Wainwright cut their target price on Nuvectis Pharma from $15.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday, August 4th.

Nuvectis Pharma Stock Performance

Shares of NVCT stock traded down $0.03 on Wednesday, hitting $6.79. The company had a trading volume of 10,092 shares, compared to its average volume of 146,477. Nuvectis Pharma has a twelve month low of $4.44 and a twelve month high of $11.80. The stock's 50-day moving average is $7.80 and its two-hundred day moving average is $8.26. The firm has a market cap of $172.87 million, a P/E ratio of -5.80 and a beta of -0.26.

Insider Transactions at Nuvectis Pharma

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri purchased 5,603 shares of Nuvectis Pharma stock in a transaction that occurred on Friday, June 20th. The shares were bought at an average price of $7.99 per share, for a total transaction of $44,767.97. Following the acquisition, the insider directly owned 2,981,806 shares in the company, valued at approximately $23,824,629.94. This trade represents a 0.19% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders bought a total of 39,045 shares of company stock worth $314,300 over the last three months. Insiders own 30.52% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in NVCT. Baldwin Wealth Partners LLC MA grew its stake in shares of Nuvectis Pharma by 0.7% in the 1st quarter. Baldwin Wealth Partners LLC MA now owns 358,461 shares of the company's stock worth $3,502,000 after buying an additional 2,500 shares during the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new stake in Nuvectis Pharma in the 2nd quarter worth $28,000. JPMorgan Chase & Co. increased its stake in Nuvectis Pharma by 3,398.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company's stock worth $47,000 after buying an additional 6,084 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Nuvectis Pharma during the fourth quarter valued at about $34,000. Finally, Blue Zone Wealth Advisors LLC purchased a new position in shares of Nuvectis Pharma during the first quarter valued at about $102,000. Hedge funds and other institutional investors own 96.77% of the company's stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.